Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.
LINZESS Growth: LINZESS prescription demand rose 12% in Q4 2024 and 11% for the full year, with new-to-brand growth of 11% in Q4 and 14% for the year.
Financial Performance: Ironwood achieved its 2024 guidance, delivering $916 million in LINZESS net sales, $351.4 million in total revenue, and $1.8 million in net income.
Apraglutide Progress: Rolling NDA submission for apraglutide has started, with completion expected in Q3 2025. Extension study data show 27 patients achieved enteral autonomy.
2025 Guidance: The company reiterated 2025 guidance for LINZESS net sales of $800–850 million, Ironwood revenue of $260–290 million, and adjusted EBITDA (excl. stock comp) of over $85 million.
Cost Structure: Recent restructuring actions will lead to a $55 million decrease in 2024 operating expenses, mainly in SG&A. Full cost savings to be realized from Q2 2025 onward.
Balance Sheet: Ended 2024 with $88.6 million cash and $385 million in drawn debt, reducing total debt by $115 million during the year.
